Cargando…

Surgical aspects in craniopharyngioma treatment

OBJECTIVES: Total surgical resection is the gold standard in the treatment of craniopharyngioma. However, there is concern that aggressive surgical resection might result in high rates of endocrinologic, metabolic, and behavioral morbidities. Subtotal resection (SR) with subsequent radiation therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujio, Shingo, Hanada, Tomoko, Yonenaga, Masanori, Nagano, Yushi, Habu, Mika, Arita, Kazunori, Yoshimoto, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668032/
https://www.ncbi.nlm.nih.gov/pubmed/34966836
http://dx.doi.org/10.1515/iss-2019-1004
_version_ 1784614485421457408
author Fujio, Shingo
Hanada, Tomoko
Yonenaga, Masanori
Nagano, Yushi
Habu, Mika
Arita, Kazunori
Yoshimoto, Koji
author_facet Fujio, Shingo
Hanada, Tomoko
Yonenaga, Masanori
Nagano, Yushi
Habu, Mika
Arita, Kazunori
Yoshimoto, Koji
author_sort Fujio, Shingo
collection PubMed
description OBJECTIVES: Total surgical resection is the gold standard in the treatment of craniopharyngioma. However, there is concern that aggressive surgical resection might result in high rates of endocrinologic, metabolic, and behavioral morbidities. Subtotal resection (SR) with subsequent radiation therapy (RT) may reduce surgical complications, but it may also increase the risk of tumor recurrence and radiation-induced side effects. Therefore, the optimal surgical strategy remains debatable. METHODS: To determine the optimal surgical strategy, we assessed the clinical courses of 39 patients (19 male patients and 20 female patients) with newly diagnosed craniopharyngioma who were treated at our institute. The median age at diagnosis was 34 years (range: 0–76 years). The median follow-up period was 8.5 years (range: 3–160 months). Our treatment strategy comprised gross total resection (GTR) for craniopharyngioma in patients that were not at surgical risk. Conversely, after adequate tumor decompression, we used RT, mainly Gamma Knife radiosurgery, in patients at risk. We divided the patients into the following three groups depending on the treatment course: GTR, SR with RT, and SR with staged surgery. We compared tumor characteristics, as well as patients’ conditions at the preoperative stage and last follow-up, among the three groups. RESULTS: There were 8, 21, and 10 patients in the GTR, SR with RT, and SR with staged surgery groups, respectively. There were no differences in the maximum tumor diameter, tumor volume, composition, and presence of calcification among the groups. Among the 39 patients, 24 underwent transcranial microsurgery and 15 underwent trans-sphenoidal surgery as the initial treatment. No cases involving surgical mortality, cerebrospinal fluid leakage, severely deteriorated visual function, or severe hypothalamic damage were observed. No tumor recurrence was noted in the GTR group. One patient required additional RT, and one patient underwent second surgery for tumor recurrence in the SR with RT group. In the SR with staged surgery group, 8 of the 10 patients eventually underwent RT, but tumor control was achieved in all patients at the latest follow-up. In this group, the third trans-sphenoidal surgery caused a severe vascular injury in one patient. At the final follow-up, 33 (85%) patients were undergoing anterior pituitary hormone replacement, and the rate of diabetes insipidus was 51%. There was no significant difference in the pituitary dysfunction rate among the groups. CONCLUSIONS: We observed a low rate of surgical complications and a sufficient tumor control rate in response to our treatment strategy. Despite attempting preservation of the pituitary stalk, we found it difficult to rescue anterior pituitary function.
format Online
Article
Text
id pubmed-8668032
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-86680322021-12-28 Surgical aspects in craniopharyngioma treatment Fujio, Shingo Hanada, Tomoko Yonenaga, Masanori Nagano, Yushi Habu, Mika Arita, Kazunori Yoshimoto, Koji Innov Surg Sci Original Article OBJECTIVES: Total surgical resection is the gold standard in the treatment of craniopharyngioma. However, there is concern that aggressive surgical resection might result in high rates of endocrinologic, metabolic, and behavioral morbidities. Subtotal resection (SR) with subsequent radiation therapy (RT) may reduce surgical complications, but it may also increase the risk of tumor recurrence and radiation-induced side effects. Therefore, the optimal surgical strategy remains debatable. METHODS: To determine the optimal surgical strategy, we assessed the clinical courses of 39 patients (19 male patients and 20 female patients) with newly diagnosed craniopharyngioma who were treated at our institute. The median age at diagnosis was 34 years (range: 0–76 years). The median follow-up period was 8.5 years (range: 3–160 months). Our treatment strategy comprised gross total resection (GTR) for craniopharyngioma in patients that were not at surgical risk. Conversely, after adequate tumor decompression, we used RT, mainly Gamma Knife radiosurgery, in patients at risk. We divided the patients into the following three groups depending on the treatment course: GTR, SR with RT, and SR with staged surgery. We compared tumor characteristics, as well as patients’ conditions at the preoperative stage and last follow-up, among the three groups. RESULTS: There were 8, 21, and 10 patients in the GTR, SR with RT, and SR with staged surgery groups, respectively. There were no differences in the maximum tumor diameter, tumor volume, composition, and presence of calcification among the groups. Among the 39 patients, 24 underwent transcranial microsurgery and 15 underwent trans-sphenoidal surgery as the initial treatment. No cases involving surgical mortality, cerebrospinal fluid leakage, severely deteriorated visual function, or severe hypothalamic damage were observed. No tumor recurrence was noted in the GTR group. One patient required additional RT, and one patient underwent second surgery for tumor recurrence in the SR with RT group. In the SR with staged surgery group, 8 of the 10 patients eventually underwent RT, but tumor control was achieved in all patients at the latest follow-up. In this group, the third trans-sphenoidal surgery caused a severe vascular injury in one patient. At the final follow-up, 33 (85%) patients were undergoing anterior pituitary hormone replacement, and the rate of diabetes insipidus was 51%. There was no significant difference in the pituitary dysfunction rate among the groups. CONCLUSIONS: We observed a low rate of surgical complications and a sufficient tumor control rate in response to our treatment strategy. Despite attempting preservation of the pituitary stalk, we found it difficult to rescue anterior pituitary function. De Gruyter 2020-10-30 /pmc/articles/PMC8668032/ /pubmed/34966836 http://dx.doi.org/10.1515/iss-2019-1004 Text en © 2020 Shingo Fujio et al., published by De Gruyter, Berlin/Boston https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License.
spellingShingle Original Article
Fujio, Shingo
Hanada, Tomoko
Yonenaga, Masanori
Nagano, Yushi
Habu, Mika
Arita, Kazunori
Yoshimoto, Koji
Surgical aspects in craniopharyngioma treatment
title Surgical aspects in craniopharyngioma treatment
title_full Surgical aspects in craniopharyngioma treatment
title_fullStr Surgical aspects in craniopharyngioma treatment
title_full_unstemmed Surgical aspects in craniopharyngioma treatment
title_short Surgical aspects in craniopharyngioma treatment
title_sort surgical aspects in craniopharyngioma treatment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668032/
https://www.ncbi.nlm.nih.gov/pubmed/34966836
http://dx.doi.org/10.1515/iss-2019-1004
work_keys_str_mv AT fujioshingo surgicalaspectsincraniopharyngiomatreatment
AT hanadatomoko surgicalaspectsincraniopharyngiomatreatment
AT yonenagamasanori surgicalaspectsincraniopharyngiomatreatment
AT naganoyushi surgicalaspectsincraniopharyngiomatreatment
AT habumika surgicalaspectsincraniopharyngiomatreatment
AT aritakazunori surgicalaspectsincraniopharyngiomatreatment
AT yoshimotokoji surgicalaspectsincraniopharyngiomatreatment